TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07896265: A Phase 3, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Olatorepatide, a GLP-1/GIP Receptor Agonist, in Participants Living With Overweight or Obesity Without Diabetes (RISE-1)

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 3000 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07896265 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07896265 Rescue Dossier →